


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-67. (Canceled)

68. (Previously presented) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;


n is 0;

R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is methyl.

69. (Previously presented) A compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;


R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is acetyl.

70-71. (Canceled)

72. (New) A pharmaceutical composition comprising a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;


R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is methyl;

and a pharmaceutically acceptable vehicle.

73. (New) A pharmaceutical composition comprising a compound of structural Formula (I):




or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;
 B is histidine;
 C is serine;
 R^1 is $C(O)CH_3$;
 R^2 is $-(CH_2)_mS(O)_nR^5$;
 m is 1;
 n is 0;
 R^3 is $-CH_2CONH_2$;
 R^4 is NH_2 ;
 R^5 is acetyl;

and a pharmaceutically acceptable vehicle.


74. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;
 A is proline;
 B is histidine;
 C is serine;
 R^1 is $C(O)CH_3$;
 R^2 is $-(CH_2)_mS(O)_nR^5$;
 m is 1;
 n is 0;
 R^3 is $-CH_2CONH_2$;
 R^4 is NH_2 ;
 R^5 is methyl.

75. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;


R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is acetyl.

76. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;


R⁴ is NH₂;

R⁵ is methyl; and

b) a pharmaceutically acceptable vehicle.

77. (New) A method for treating lung cancer in a patient comprising administering to a patient having lung cancer a therapeutically effective amount of a pharmaceutical composition comprising

a) a compound of structural Formula (I):



or a pharmaceutically available salt, solvate or hydrate thereof wherein:

a, b, x, y and z are 1;

A is proline;

B is histidine;

C is serine;

R¹ is C(O)CH₃;

R² is -(CH₂)_mS(O)_nR⁵;

m is 1;

n is 0;

R³ is -CH₂CONH₂;

R⁴ is NH₂;

R⁵ is acetyl; and

b) a pharmaceutically acceptable vehicle.

78. (New) The method of any one of claims 74-77 wherein the patient is a human.